Results 11 to 20 of about 8,460 (122)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study [PDF]

Gut, 2014
OBJECTIVE: Budesonide MMX is a novel oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon. This study compared the efficacy of budesonide MMX with placebo in patients with active, mild-to-moderate ...
Silvio Danese, Peter Gibson, Simon Travis   +2 more
exaly   +3 more sources

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies [PDF]

Alimentary Pharmacology and Therapeutics, 2015
BACKGROUND: Conventional oral corticosteroids are effective at reducing inflammation associated with ulcerative colitis (UC); however, systemic adverse effects limit their use.
Silvio Danese, Simon Travis, William Jeffery Sandborn   +2 more
exaly   +4 more sources

Budesonide ММХ in the treatment of ulcerative colitis: real world clinical practice

Alʹmanah Kliničeskoj Mediciny, 2019
Rationale: Mild and moderate ulcerative colitis (UC) is conventionally treated with oral and rectal 5-aminosalicylic acid (5-ASA) formulations and, if ineffective, with systemic glucocorticosteroids.
P. A. Makarchuk, O. S. Britkina, E. A. Belousova   +2 more
doaj   +5 more sources

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis

Clinical and Experimental Gastroenterology, 2014
Marisa Iborra,1 Diego Álvarez-Sotomayor,2 Pilar Nos1 1Gastroenterology Unit, Department of Digestive Disease, Centro de investigación biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), La Fe University and ...
Iborra M, Álvarez-Sotomayor D, Nos P   +2 more
doaj   +1 more source

A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®^MMX®) for active, mild-to-moderate ulcerative colitis. [PDF]

United European Gastroenterol J, 2019
Background Cortiment®$^{MMX®}$ (budesonide MMX®) is currently approved for the induction of remission in mild-to-moderate ulcerative colitis (UC) patients when 5-ASA treatment is not sufficient. Data in real-life settings are lacking. Methods This was
Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L.   +10 more
europepmc   +2 more sources

Drugs in focus: Budesonide and its role in paediatric gastrointestinal disorders. [PDF]

J Pediatr Gastroenterol Nutr
Abstract Budesonide is a glucocorticoid with strong topical anti‐inflammatory properties and minimal systemic effects due to extensive first‐pass hepatic metabolism. It is designed for targeted delivery within the gastrointestinal (GI) tract and is available in oral and rectal formulations.
Aziz S, Puoti MG, Assa A, Misak Z, Mas E, Borrelli O, Dolinšek J, Martin-de-Carpi J, Scheers I, Tzivinikos C, Homan M, Strisciuglio C.   +11 more
europepmc   +2 more sources

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. [PDF]

BMJ Open Gastroenterol, 2016
peer reviewedINTRODUCTION: A study has been developed to assess the use and effectiveness of budesonide MMX for mild-to-moderate active ulcerative colitis (UC) in routine clinical practice. METHODS AND ANALYSIS: A prospective, multicentre, observational,
Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L.   +9 more
europepmc   +2 more sources

Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis. [PDF]

JGH Open
ABSTRACT Aims Proton pump inhibitors (PPIs) and potassium‐competitive acid blockers (PCABs) are widely used for acid‐related disorders. Recent studies have raised concerns that acid suppression may alter gut microbiota and drug pharmacokinetics, potentially influencing therapeutic outcomes in patients with inflammatory bowel disease.
Otagiri S, Ito T, Yagisawa K, Sugitani A, Maemoto A.   +4 more
europepmc   +2 more sources

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. [PDF]

United European Gastroenterol J, 2022
Abstract We performed a systematic review to investigate the definition of mild to moderate active ulcerative colitis (UC), and to describe predictors of good response to treatment in clinical trials assessing 5‐ASA and/or budesonide. Thirty‐nine randomized controlled trials were included.
Caron B, Jairath V, D'Amico F, Paridaens K, Magro F, Danese S, Peyrin-Biroulet L.   +6 more
europepmc   +2 more sources

Optimization of approaches to the treatment of mild to moderate ulcerative colitis

Лечащий Врач, 2021
Ulcerative colitis is an autoimmune disease of the colon, manifested by the development of non-specific inflammation of its mucous membrane with a mandatory lesion of the rectum.
S. S. Belous, O. V. Knyazev
doaj   +1 more source